Six (32%) participants were on mTOR inhibitors for indications of SEGA (2/6), epilepsy (1/6), renal AMLs (2/6) or lymphangioleiomyomatosis (LAM) (1/6). The gene discussed is MTOR; the disease is lymphangioleiomyomatosis.